IS30XY

IS30XY is a preclinical-stage diagnostic radiopharmaceutical being developed by iSeek Biopharma for Positron Emission Tomography (PET) imaging of inflammation. The agent is part of a pipeline of radiopharmaceuticals designed to target receptors on leukocytes, such as the Integrin alpha-L/beta-2 (LFA-1) receptor, to enable high-sensitivity visualization of inflammatory processes. By tracking leukocyte recruitment and localization, IS30XY aims to provide a non-invasive tool for the diagnosis and monitoring of various inflammatory conditions. While the specific molecular target for IS30XY is not explicitly disclosed in the company's public pipeline, iSeek Biopharma's core technology platform centers on targeting the LFA-1 receptor on leukocytes.